Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

ChemoMetec A/S (CHEMM)

Copenhagen
Currency in DKK
Disclaimer
286.60
+4.20(+1.49%)
Closed

CHEMM Comments

Twitter - Chemometec - Come and meet us at booth no. 19 at the CAR-TCR Summit Europe, which will be held February 21 – 23, 2023, in London, UK.
Cordis - Horizon - Circular Vision - EU project with 4 million Euro to be presented 31. March 2024.
Chemometec presents for the tasks - NC202, Xcytomatic 40 and Xcyto5 and Xcyto10. The latter used in the patent taking of patterns.Eu is a very active contributor and the first cancer desease is under research. The results to be presented 2024 in collaboration with Roche Diagnostics.
Cirkular DNA - a biomarker - ready as diagnostic tool in 2024 ?Circular DNA is emerging as a novel biomarker for many types of cancer and inflammatory disorders. However, we lack the technology for detecting circular DNA and for generating appropriate disease models. To address this problem, the EU-funded CIRCULAR VISION project will use lung cancer and inflammatory bowel disease to investigate the link between disease and circular DNA. Scientists will combine microfluidics, DNA sequencing and bioinformatics to identify new biomarkers and develop novel approaches for cancer diagnosis. The generated technology will pave the way for future research and drug development in the field.
2022 was a record year for the approval of never-before-authorized gene therapies, with three new therapies approved to treat rare diseases and another approved to treat bladder cancer. Additionally, five therapies that had already been approved in the US or Europe were authorized for the first time in a new geography or for another indication.But this is just the initial swell of the coming wave. As of this writing, as many as 13 brand new cell or gene therapies could be approved for use in the US, Europe, or both by the end of 2023. We are in reach of the FDA’s often-cited 2019 prediction that it would approve 10-20 new cell and gene therapies a year by 2025.
There are now six FDA-approved CAR-T cell therapies available to patients in both the US and Europe to treat various blood cancers. They are but one part of a growing set of promising cell and gene therapies to address rare and prevalent conditions.There are over 2,000 clinical trials happening today, with 200 in Phase III – a wave of hope for patients waiting on durable, possibly curative treatments. But investment, policy, and regulatory challenges remain for the sector, and many patients will not benefit unless we modernize our approach to health care.
Report headlines to read, .. search for .. CAR-T Therapy market is projected to grow at a CAGR of 42.95% by 2032: Visiongain Reports Ltd
Weekly macd once again pointing upwards. The astonishing growth in Car-t and Gene therapeutics with + 40 % continues. The revolution in cirkular DNA diagnostics methods will in 2024 contribute to the growth. Together with the danish universities and ROCHE DIAGNOSTICS methods in cancer diagnostics and residual control will revolutionize medical timeframes a survivability. Cirkular DNA is to be found in 50 % of all cancer expressions. Due to their high technology and vast patenting Chemometec is ready to profit from these revolutionary methods. Read more at Chemotetec.dk
Confirmed break up from negative trade channel and weekly macd accelerating. Chart: https://invst.ly/xc7vy
First halv year .. Interim .. growth 58 % and ebitda growth from 50 to 55 %. Preparing to launch the first automatick industrial scale advanced cell counter.
Jan 28 - Chemometec - another upward adjustment by around 5-7 % in turnover and ditto results.
Weekly ( Heavy ) macd bottoming out, https://invst.ly/x8vtp
BLACKROCK .. has today announced they have passed over the 5 % of stockholding.
Chemometec is the market leader in this segment of cell counting and analysis and is therefore adapting to the same growth rates.The company is very well performing and due to conservative estimates a solid investment. You should take a look.
The global market for chimeric antigen receptor (CAR) T-cell therapy is estimated to grow from $1.5 billion in 2021 to reach $7.6 billion by 2026, at a compound annual growth rate (CAGR) of 39.1% during 2021-2026.
Chemometec recently raised targets about 10 %.
The global market for chimeric antigen receptor (CAR) T-cell therapy is estimated to grow from $1.5 billion in 2021 to reach $7.6 billion by 2026, at a compound annual growth rate (CAGR) of 39.1% during 2021-2026.
There is only one way in this stock
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.